

Curriculum Vitae*

(*a more detailed description also covering my additional published work in national journals and conferences is presented in my CV in Greek)

Name: **Ioannis S. Vizirianakis, Ph.D.**, Associate Professor of Molecular Pharmacology & Pharmacogenomics

Homepage/profile: <http://www.pharm.auth.gr/en/faculty/764>

LinkedIn: <https://www.linkedin.com/in/ioannis-vizirianakis-035a1a50>

ResearchGate: https://www.researchgate.net/profile/Ioannis_Vizirianakis

Contact

Email: ivizir@pharm.auth.gr

Tel. +30 2310 997658; mobile: +30 6976695932

Address

Laboratory of Pharmacology, Department of Pharmaceutical Sciences, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece

Education

1981: B.Sc. of the Dept. of Pharmaceutical Sciences, Aristotle University of Thessaloniki (AUTH), Greece (*Graduation rank: 1st in my class*)

1991: Doctorate thesis in Pharmacology, Dept. of Pharmaceutical Sciences, Aristotle University of Thessaloniki (AUTH), Greece

Academic Positions

1982-1993: Research assistant, Dept. of Pharmaceutical Sciences, AUTH
1993-2003 Lecturer in Pharmacology, Dept. of Pharmaceutical Sciences, AUTH

1997-1999 Postdoctoral Fellow, Tumor Biology Laboratory, Oral Cancer Research Center, University of California, at San Francisco (UCSF), San Francisco, CA, U.S.A. (*Sabbatical*)

2000 *Unsuccessful attempt for promotion to Assistant Professor*

2004-2007 Assistant Professor of Pharmacology, Dept. of Pharmaceutical Sciences, AUTH

2008- Today Associate Professor of Molecular Pharmacology & Pharmacogenomics, Dept. of Pharmaceutical Sciences, AUTH

2014 *Unsuccessful attempt for promotion to Full Professor*
(Minutes of the electorate seven-member committee meeting held on July 22, 2014 at: http://users.auth.gr/ivizir/MINUTES_ELECTORATE_COMMITTEE_VIZIRIANAKIS_PROMOTION-ENG2014.pdf)

2015-2016 Associate Professor, Department of Life and Health Sciences, University of Nicosia, 1700 Nicosia, Cyprus (*Sabbatical*)

Research Experience

- 1982-1985: Research assistant in Pharmaceutical Chemistry (AUTH)
1985-1991: Research assistant in Pharmacology (AUTH)
1991-1993: Postdoctoral fellow in Pharmacology (AUTH)
1997-1999: Postdoctoral Fellow, UCSF, San Francisco, CA, USA

Sabbatical

- 1997-1999 Tumor Biology Laboratory, Oral Cancer Research Center, Department of Stomatology, University of California, at San Francisco (UCSF), San Francisco, CA, U.S.A
2015-2016 Department of Life and Health Sciences, University of Nicosia, 1700 Nicosia, Cyprus

Fellowships

- 1978-1981 Fellowship during my undergraduate studies, AUTH
1998 Research Grand Award, University of California, Cancer Coordinating Committee, UCSF, USA
(Chancellor: Prof. Dr. J. Michael Bishop, Nobel Laureate)

Editorial Board member in peer-review journals

- Frontiers of Pharmacology & Pharmacogenetics
- World Journal of Pharmacology

Reviewer in peer-review journals (selected)

- Trends in Pharmacological Sciences
- Pharmacogenomics
- Expert Opinion on Drug Metabolism and Toxicology
- Personalized Medicine
- Medical Science Monitor
- Drug Design Reviews-On line
- Cytotherapy
- Current Cancer Drug Targets
- European Journal of Medicinal Chemistry
- Nanomedicine: Nanotechnology, Biology, and Medicine (Nanomedicine: NBM)
- International Journal of Cancer
- Current Drug Delivery
- WIREs Nanomedicine and Nanobiotechnology
- Journal of Personalized Medicine
- Frontiers in Pharmacogenetics & Pharmacogenomics
- Advanced Drug Delivery Reviews
- Nanomedicine (London)
- Journal of Nanoparticle Research
- Journal of Leukemia
- Journal of Cellular and Molecular Medicine
- Frontiers in Oncology
- Journal of Biological research-Thessaloniki

Member in Scientific Societies

1992 - Today	The Hellenic Society of Biochemistry and Molecular Biology
1995 - November 2014	The Greek Society of Pharmacology and Clinical Pharmacology
1998 - Today	The American Society for Cell Biology
2002 - Today	European Association of Pharma Biotechnology
2005 - Today	Northern Greece Society of Atherosclerosis
2005 - Today	American Association of Pharmaceutical Scientists
2016 - Today	Hellenic Bioinformatics (Co-Founding member)

Isolation and characterization of Genes, RNA molecules submitted to DNA data banks

Within the frame of my published work, the following genetic data have been submitted in DNA data banks (1-4 before 2000):

1. Murine ribosomal protein S5 mRNA (full length) **Gen/EMBL: Y12431**
2. Murine ribosomal protein L35a mRNA (full length) **Gen/EMBL: Y16430**
3. Human alpha-7 integrin mRNA (full length) **Gen/EMBL: AF072132**
4. Murine B22 subunit mRNA of NADH: Ubiquinone Oxidoreductase (complex I) (partial sequence) **Gen/EMBL: AJ300739**
5. Four non-coding RNA transcripts with accession numbers: **FM992847, FM992848, FM992849, and FM992850**

Member of the organizing/scientific committees in meetings

A) International Scientific meetings

- 1) BBBB International Conference. *“From Drug Discovery and Formulation Strategies to Pharmacokinetics-Pharmacodynamics”*, September 26-28, 2013, Athens (BBBB-EUFEPS) (Local Organizing Committee)
- 2) COST Action CM1106 3rd Working Group Meeting. *“Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells”*, 26-27 March 2015, Athens, Greece
- 3) 8th International Symposium. *“Computational Methods in Toxicology and Pharmacology Integrating Internet Resources”* (CMTPI-2015), June 21-25, 2015, Chios Island, Greece
- 4) Hellenic Bioinformatics 09 Conference: *“Bioinformatics as a growth engine for Greece”*. November 19-21, 2016, Thessaloniki, Greece. (Organizing Committee)
- 5) Hellenic Bioinformatics 10 Conference: *“Bioinformatics Applications in Life Sciences: In Health, Biodiversity and Environment”*. September 6-8, 2017, Heraklion, Crete, Greece (Organizing Committee)

B) National scientific meetings

Eight (8) national scientific meetings (**1** of the “Greek Pharmacological Society” in 2004 and **7** of the “Northern Greek Atherosclerosis Society” from 2006-2012).

Member of drug regulatory bodies-Committee member

- | | |
|-----------|--|
| 2005-2011 | Member of the “Pharmacovigilance Committee”, National Organization of Medicines (Greece) |
| 2015- | Member of the AUTH International Graduate Studies Committee |

Organization of Continuous Education (CE) Programs

- 2010 Coordinator and full-responsible person in establishing the CE program for pharmacists in Northern Greece in collaboration with the “US Pharmacist” and “Medscape” (URL: <http://www.fsrodopis.gr/sfe/default.aspx>)
- 2016 Scientific coordinator for the section “Pharmacogenetics – Pharmacogenomics” of the CE program on “Medical Genetics” , at the School of Medicine, University of Ioannina, Greece (URL: <http://www.medical-genetics-uoι.net/>)

Theme Editor in Peer-review Journals

Journal: Advanced Drug Delivery Reviews; Theme Issue Title: “*Personalized Nanomedicine*”; Theme Editors: Ioannis S. Vizirianakis and Dimitrios Fatouros; Publication Date: Volume 64, Issue 13, Pages 1359-1544 (October 2012).

Book Editor (in English)

Book Title: “*Personalized Medicine: Advances in Nanotechnology, Drug Delivery and Therapy*”; Editor: Ioannis S. Vizirianakis; Publisher: Pan Stanford Publishing; USA & Singapore; Pages 1560; Illustrations 136 (48 in color). Publication Date: January 30, 2014. Print ISBN: 9789814411196; eBook ISBN: 9789814411202; DOI: 10.4032/9789814411202

(Book review: *Fishwick D. (2015). Occup Med (Lond) (2015) 65 (3): 263. DOI: <https://doi.org/10.1093/occmed/kqu199>*

(URL: <https://academic.oup.com/occmed/article/65/3/263/1479346/Handbook-of-Personalized-Medicine-Advances-in>

Book Editor (in Greek)

Book Title: “*Clinical Pharmacokinetics: Basic principles of pharmaceutical care in clinical practice*”; Publisher: Stamoulis-Sartinas Publishing; Thessaloniki Greece; Pages 392; Tables 42; Figures 21. Publication Date: 2016 (3rd edition). ISDN: 978-618-5161-29-3.

Director/Coordinator of postgraduate studies

2011 - 2015 Coordinator in the program curriculum for “Pharmacology and Therapeutics” at the School of Pharmacy, AUTH

Supervisor and/or committee member in MSc and/or PhD theses

- Supervisor in 14 M.Sc. theses (10 completed and 4 in progress) and in 3 PhD, thesis (1 completed)

(*First year implementation for graduate program in School of Pharmacy, AUTH on 2002-2003 (I was able to act so, since receiving ass. prof. position on 2003)*)

- Supervising and/or examination committee member in 12 Ph.D. theses (completed) and 14 M.Sc. theses (completed)

(*First year implementation for graduate program in School of Pharmacy, AUTH on 2002-2003)*)

- Supervisor in 15 pharmacy diploma thesis (10 completed)

(*First year implementation for diploma thesis in School of Pharmacy, AUTH on 2010-2011)*)

Grant Awards and Funding Proposals

- 1989-1991: Commission of European Community Research Grant (Biotechnology Action Program) (BAP); Principal Investigator: A.S. Tsiftoglou
- 1991-1993: Commission of European Community Research Grant (BRIDGE R and D Program on Biotechnology); Principal Investigator: A.S. Tsiftoglou
- 1994-1997: Greek Secretariat for Science and Technology (EIIET II); Principal Investigator: A.S. Tsiftoglou
- 1997-1999: Greek Secretariat for Science and Technology (EPEAK I); Principal Investigator: S. Sklaviadis
- 1998-2001: Greek Secretariat for Science and Technology (EKBAN); Principal Investigator: A.S. Tsiftoglou
- 1998 Research Grand Award (Postdoctoral Fellowship) from the University of California Cancer Coordinating Committee, UCSF, CA, U.S.A. (Chancellor: Prof. Dr. J. Michael Bishop, Nobel Laureate)
- 2000-2002: Greek Secretariat for Science and Technology (PENED); Principal Investigator: A.S. Tsiftoglou
- 2002-2004: Greek Secretariat for Science and Technology (Cooperative research grants between Greece-Russia); Principal Investigator: T. Choli-Papadopoulou
- 2002-2005: Greek Secretariat for Science and Technology (EPEAK II); Principal Investigator: E. Chiotellis
- 2003-2005: Greek Secretariat for Science and Technology (EPEAK II); Principal Investigator: A. Kanellis
- 2005-2008: Greek Secretariat for Science and Technology (EPEAK II); Principal Investigator: A.S. Tsiftoglou
- 2007-2009: CancerNet – Network of Excellence, Research Committee of AUTH (Coordinator: A.S. Tsiftoglou) (Co-founding member)
- From 2012 Hematopoiesis Initiative Network (HemIN) (Co-founding member) (<http://hemin-net.pharm.auth.gr/>)
- 2009-2017 Principal Investigator: Project entitled “*Assessment of herb-drug interactions in vitro and in vivo at the molecular and clinical level*” successfully assessed by the international consortium for the development of “*Simcyp – Population Based Pharmacokinetic Modeling and Simulation*” (Academic license agreement: July 2009). (URL: <http://www.simcyp.com/>).
- 2011** ***Short-listing for the “Simcyp teaching award”***
- 2011 Principal Investigator: Project entitled: “*Assessment of ribosomal protein RPS5 and RPL35a functions in MEL cell erythroid differentiation with potential clinical relevance in myelodysplastic syndromes*”; Research Committee of AUTH.
- 2011 Principal Investigator: Project entitled: “*Clinical assessment of gene expression molecular signatures in patients suffering hematopoiesis disorders*”; Genesis Pharma.
- 2012- 2016: Member of the management committee (MC) in the COST Action CM1106 entitled “*Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells*” (StemChem) grant funded by the EU Framework Programme.
- 2014-2015 Collaborator in the funded project: “*Microporous inorganic materials (zeolites) for the oral delivery of poorly soluble drugs*”. Coordinator: D. Fatouros. ARISTEIA II (18 months).

- 2015 Collaborator in the pharmaceutical industry-oriented funded project: “Development of drug delivery formulations for poorly-soluble active substances”. Rontis Pharma. Coordinator: D. Fatouros.
- 2016 Collaborator in the pharmaceutical industry-oriented funded project: “Permeability assessment of solid drug formulations in cell cultures”. Pharmathen Pharma. Coordinator: D. Fatouros.
- 2016-2017 Principal Investigator: Industry-oriented funded project: “Assessment of molecular signatures of circulating tumor cells in cancer therapy”. Biogenea Pharmaceuticals.
- 2017 Exploitation of genetic and clinical data in the therapeutic outcome of heart disease suffering Greek population. Hellenic Cardiological Foundation. (Coordinator: G. Sianos).
- 2017 Risk assessment factors contributing to angina complexity in the Greek population: SYNTAX score, clinical evaluation and pharmacogenetics analysis. Hellenic Cardiological Society. (Coordinator: G. Sianos).

Reviewer-evaluator in funding bodies

Grant applications (for several years) from the “Greek Secretary of Research and Technology”, and the “Greek Ministry of Education”; NASA Postdoctoral Program; European Commission H2020-FET Proactive call.

Academic positions and research interests in brief

I currently serve as an Associate Professor in Molecular Pharmacology and Pharmacogenomics at Aristotle University of Thessaloniki (A.U.TH.), School of Pharmacy. After receiving my degree in Pharmacy (1981) in A.U.TH., I joined the Department as research assistant (1985-1990), obtained a Ph.D. (1991) in Biochemical Pharmacology and finally was assigned as Lecturer (1993) and then Assistant Professor (2003) in Pharmacology. I received a research grant award (1998) from Cancer Coordinating Committee upon my sabbatical at the Tumor Biology Laboratory, UCSF. My long-term research interests focus on: a) the so-called “differentiation therapy of cancer” and include the development of innovative chemical inducers of differentiation of leukemia cells through the understanding of crucial molecular mechanisms that govern leukemia cell initiation, unrestricted growth as well as blockade of differentiation and apoptosis; b) the development of innovative therapeutics for erythropoiesis disorders, e.g. ribosomopathies, through uncovering specific molecular pathophysiological mechanisms and identification of potential pharmacological targets for clinical validation; c) the integration of nanomedicine, pharmacogenomics and personalized medicine concepts in new drug development, drug delivery and clinical practice; and d) predictive population-based physiologically-based PD/PK models through use of Simcyp platform for new drug development, delivery and individualization of dosage regimens.

Teaching experience and course development

I. At the School of Pharmacy, Aristotle University of Thessaloniki

[For a more detailed description, see at the “Syllabus” (pp. 3-11) in my profile webpage at:

http://www.pharm.auth.gr/sites/default/files/Cumulative%20academic%20work_Vizirianakis.pdf]

- A. Pharmacy undergraduate curriculum courses (more than 25-year experience):
- Course: Introduction to Pharmaceutical Sciences: historical and regulatory issues (1st year students)
Development of lectures
 - Course: Pharmacology I & II (Biochemical, Molecular and Clinical) (3rd year students)
Development of lectures as well as practical courses-exercises to assess pharmacological response by using in vitro cell culture models, molecular techniques and/or co-evaluating pharmacogenomics data (selective biomarkers, etc)
 - Course: Clinical Pharmacokinetics (4th year students)
Editing of a 290-page related book in Greek (2nd edition; 2010)
Development of lectures as well as practical courses-exercises on population-based Simcyp platform (predictive PB/PD/PK models for drug behaviour as well as drug interaction prediction and assessment profiles in clinical practice)
- B. Pharmacy postgraduate curriculum courses (more than 12-year experience courses)
- Course: Molecular Pharmacology and Pharmacogenetics
Development of lectures as well as practical courses-exercises
 - Course: Drug Interactions
Development of lectures as well as practical courses-exercises

Specification of the content of the lectures for the “Pharmacy undergraduate curriculum”

1. Course: Introduction to Pharmaceutical Sciences: historical and regulatory issues

The new drug development era: from pharmaceutical sciences and regulatory issues to clinical trials and market approval; Pharmacovigilance issues and the role of pharmacists

2. Course: Pharmacology I & II (Biochemical, Molecular and Clinical)

Pathophysiology of heart failure – Positive inotropic drugs; Pathophysiology of hypertension – Antihypertensive drugs; Clinical pharmacology of antihypertensive drugs – Drug selection upon prescription; Physiology of urine production (diuresis) and pathophysiology – Diuretic drugs; Clinical pharmacology of diuretic drugs – Drug selection upon prescription; Vasodilating agents – Anti-angina drugs; Antiarrhythmic agents; Histamine and antihistaminic drugs; Ergot alkaloids; Bronchodilator drugs and other agents used for the treatment of asthma; Local anesthetics; Anti-depressant drugs and anti-anxiety agents; Psychotropics; Non-opioid analgesics - NSAIDs – Anti-gout and anti- hyperuricaemia drugs; Cancer chemotherapy; Immunosuppressive drugs.

Laboratory work / Practical courses

- a) Isolation of genomic DNA from cell cultures and electrophoretic analysis: Study of drug actions
- b) Electrophoretic analysis of protein drug receptors
- c) Antineoplastic chemotherapeutic drugs: Evaluation of cytotoxic activity of drugs by using leukemic cell cultures in vitro
- d) Genotyping and mapping analysis of specific DNA fragments for pharmacogenomics applications

Tutorials

- a) Pharmacology: The advent of pharmacogenomics to improve new drug development era
- b) Pharmaceutical care of hypertension: Towards evaluating gene-drug interactions to improve therapy profiles
- c) Cancer pharmacogenomics
- d) Pharmacovigilance: The case of NSAIDs

3. Course: Clinical Pharmacokinetics

Protein binding of drugs; Intestine drug metabolism; Hepatic drug metabolism; Assessment of drug interactions mechanisms; Drug-drug drug-food and drug-herb interactions; Mechanisms involved in the emergence of adverse drug interactions, Pharmacogenomics and adjustment of drug dosage delivery; PK-based drug prescription principles; Pharmacoeconomics issues in drug delivery; Clinical relevance of drug metabolizing enzymes and transporters genetic polymorphism; Individualizing drug delivery dosage schemes in clinical practice; Environmental toxicants and drug delivery.

-Examples of pharmacokinetic case studies being discussed:

- a) Removal of cerivastatin from the market; b) Removal of rofecoxib from the clinical practice; c) Drug-induced QT-elongation and drug cardiotoxicity; and d) PK-based methodological improvements applied upon indinavir new drug development.

Tutorial / Practical courses

-Application of population pharmacokinetics platform Simcyp to assess clinically relevant drug interactions: a) Basic principles of population pharmacokinetics and demonstration of Simcyp platform; b) PK/PD evaluation of midazolam administration in various populations; and c) PK/PD evaluation upon co-administration of midazolam with ketoconazole in various populations.

Specification of the content of the lectures for the “Pharmacy postgraduate curriculum”

1. Course: Molecular Pharmacology and Pharmacogenetics

Introduction to molecular pharmacology; New drug development era: Advancements in molecular pharmacology, informatics, nanotechnology and genomics; Druggability and new pharmacological classes of drugs i.e. antisense RNAs and siRNAs, aptamers; Pharmacogenetics/Pharmacogenomics: From pharmacological knowledge enrichment to practical clinical utility; Drug resistance mechanisms and consequences to chemotherapy in clinical practice; Pharmaceutical biotechnology issues; Pharmacology and pharmacogenomics of cardiovascular system: Focus on innovative drug development and drug delivery; Assessment of ADRs in clinical practice: Focus on drug interactions and pharmacogenomics; Pharmacology of NSAIDs: From pharmacological and pharmacovigilance issues to pharmacogenomics clinical utility.

2. Course: Drug Interactions

Introduction to drug interaction issues and their clinical relevance in modern therapeutics; Drug interactions assessment methodologies; Clinical evaluation of drug-drug, drug-food and drug-herb interactions in routine healthcare; Pharmacovigilance: Eudravigilance and WHO regulatory issues; Molecular mechanisms involved in drug interactions; Pharmacology and pharmacogenomics of drug transporters, metabolizing enzymes and receptors; Personalized medicine: Clinical status for individualizing drug prescription dosage schemes; Case study for

the cholinesterase inhibitors: Assessment and evaluation of various drugs interactions seen in clinical practice; CYP isoenzymes and genetic polymorphism: Clinical consequences in clinical practice; Drug-induced cardiotoxicity: Elongation of QT interval and ICH-E14 guidance; Assessment of pharmacovigilance data from ADROIT drug database; Case study for the use of clinical- and genomics-based algorithms to guide warfarin dose in individual patients; Simcyp-population based platform: Clinical usefulness and new drug development capabilities; Drug-induced hepatotoxicity: Molecular pharmacology, pharmacogenomics and clinical evaluation; Drug-induced kidney failure: Molecular pharmacology, pharmacogenomics and clinical evaluation; Case study for the consequences of tamoxifen-paroxetine interaction in oncology: assessment of pharmacological and pharmacogenomics data; Practical utility of various sources to predict and evaluate drug interactions in the clinical settings.

II. Teaching experience in other national or international undergraduate/postgraduate programs

- a. Postgraduate program at the School of Biology, Aristotle University of Thessaloniki, Greece
- b. Postgraduate program at the School of Medicine, Democritus University of Thessaloniki, Greece
- c. Undergraduate Pharmacy program, Nicosia University Cyprus
[Academic year 2015-2016; development and teaching of nine (9) different courses]

Publications

Doctorate thesis

Vizirianakis I.S. (1991). A STUDY ON THE MECHANISM OF ACTION OF NUCLEOSIDE METHYLATED DERIVATIVES ON ERYTHROLEUKEMIA (MEL) CELL DIFFERENTIATION

DOI [10.12681/eadd/1908](https://doi.org/10.12681/eadd/1908)

<http://phdtheses.ekt.gr/eadd/handle/10442/1908>

A1. Research Articles in peer-review journals

1. Mylonas S., Valavanidis A., Dimitropoulos K., Polissiou M., Tsiftoglou A.S. and **Vizirianakis I.S.**, (1988). Synthesis, Molecular Structure, Determination and Antitumor Activity of Platinum(II) and Palladium(II) Complexes of 2-substituted Benzimidazole, *J. Inorg. Biochem.*, 34: 265-275. (*Impact Factor 2015: 3.205*)
2. **Vizirianakis I.S.**, Wong W. and Tsiftoglou A.S. (1992). Analysis of inhibition of commitment of murine erythroleukemia (MEL) cells to terminal maturation by N⁶-methyladenosine. *Biochem. Pharmacol.*, 44: 927-936. (*Impact Factor 2015: 5.091*)
3. **Vizirianakis I.S.** and Tsiftoglou A.S., (1995). N⁶-methyladenosine inhibits murine erythroleukemia cell maturation by blocking methylation of RNA and memory *via* conversion to S-(N⁶-methyl)-adenosylhomocysteine. *Biochem. Pharmacol.*, 50: 1807-1814. (*Impact Factor 2015: 5.091*)
4. **Vizirianakis I.S.** and Tsiftoglou A.S., (1996). Induction of murine erythroleukemia cell differentiation is associated with methylation and differential stability of polyA⁺ RNA transcripts. *Biochim. Biophys. Acta - MCR*, 1312: 8-20. (*Impact Factor 2015: 5.128*)
5. **Vizirianakis I.S.**, Pappas I.S., Gougoumas D.D. and Tsiftoglou A.S. (1999). Expression of ribosomal protein S5 cloned gene during differentiation and apoptosis in murine erythroleukemia (MEL) cells. *Oncol. Res.*, 11(9): 409-419. (*Impact Factor 2015: 3.957*)
6. **Vizirianakis I.S.**, Chen Y-Q., Yao C-C., Ziober B.L., Tsiftoglou A.S., and Kramer R.H. (2001). Transfection of MCF-7 carcinoma cells with human integrin $\alpha 7$ cDNA promotes adhesion to laminin. *Arch. Biochem. Biophys.*, 385: 108-116. (*Impact Factor 2015: 2.807*)
7. Pappas I.S., **Vizirianakis I.S.** and Tsiftoglou A.S. (2001). Cloning, sequencing and expression of a cDNA encoding the mouse L35a ribosomal protein during differentiation of murine erythroleukemia (MEL) cells. *Cell Biol. Int.*, 25: 629-634. (*Impact Factor 2015: 1.663*)
8. Gougoumas D.D., **Vizirianakis I.S.** and Tsiftoglou A.S. (2001). Activation of prion protein (PrP) gene in growth arrested and differentiated mouse and human neoplastic cells. *Exp. Cell Res.*, 264: 408-417. (*Impact Factor 2015: 3.378*)

9. **Vizirianakis I.S.**, Pappas I.S. and Tsiftoglou A.S. (2002). Differentiation-dependent repression of c-myc, B22, COX II and COX IV genes in murine erythroleukemia (MEL) cells. *Biochem. Pharmacol.*, 63: 1009-1017. (*Impact Factor 2015: 5.091*)
10. **Vizirianakis I.S.**, Chen Y-Q, Katak S.S., Tsiftoglou A.S. and Kramer R.H. (2002). Dominant-negative E-cadherin alters adhesion and growth of MCF-7 breast carcinoma cells. *Int. J. Oncol.*, 21: 135-144. (*Impact Factor 2015: 3.018*)
11. Yeh M-G., Ziober B.L., Liu, B., Lipkina, G., **Vizirianakis I.S.** and Kramer R.H. (2003). The $\beta 1$ cytoplasmic domain regulates the laminin-binding specificity of the $\alpha 7X1$ integrin. *Mol. Biol. Cell* 14: 3507-3518. (*Impact Factor 2015: 4.037*)
12. **Vizirianakis I.S.** and Tsiftoglou A.S. (2005). Blockade of murine erythroleukemia cell differentiation by hypomethylating agents causes accumulation of discrete small poly(A)⁻ RNAs hybridized to 3'-end flanking sequences of β^{major} globin gene. *Biochim. Biophys. Acta - MCR*, 1743: 101-114. (*Impact Factor 2015: 5.128*)
13. Pappas I.S., Lambris J., Vizirianakis I.S., Winter MS and Tsiftoglou A.S. (2005). Mechanisms of action of differentiation inducers: Detection of an inducer-binding protein in murine erythroleukemia cells. *Oncol. Res.*, 15: 21-37. (*Impact Factor 2015: 3.957*)
14. Gougoumas, D.D., **Vizirianakis, I.S.**, Trivaii, I.N. and Tsiftoglou, A.S. (2007). Activation of *Prn-p* gene and stable transfection of Prn-p cDNA in leukemia MEL and neuroblastoma N2a cells increased production of PrPC but not prevented DNA fragmentation initiated by serum deprivation. *J. Cell. Physiol.*, 211:551-559. (*Impact Factor 2015: 4.155*)
15. Matragkou CN, Papachristou ET, Tezias SS, Tsiftoglou AS, Choli-Papadopoulou T and **Vizirianakis IS.** (2008). The potential role of ribosomal protein S5 on cell cycle arrest and initiation of murine erythroleukemia cell differentiation. *J. Cell. Biochem.* 104:1477-1490. (*Impact Factor 2015: 3.446*)
16. Spanakis M, **Vizirianakis IS**, Mironidou-Tzouveleki M, Niopas I. (2009). A validated SIM GC/MS method for the simultaneous determination of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in biological matrices and its application to in vitro CYP2D6 and CYP3A4 inhibition study. *Biomed. Chromatogr.*, 23:1131-1137. (*Impact Factor 2015: 1.729*)
17. Matragkou C, Papachristou H, Karetsoy Z, Papadopoulos G, Papamarcaki T, **Vizirianakis IS**, Tsiftoglou AS, Choli-Papadopoulou T. (2009). On the Intracellular Trafficking of Mouse S5 Ribosomal Protein from Cytoplasm to Nucleoli. *J. Mol. Biol.*, 392:1192-1204. (*Impact Factor 2015: 4.517*)
18. Termentzi A., Khouri I., Gaslonde T., Prado S., Saint-Joanis B., Bardou F., Amanatiadou E.P., **Vizirianakis I.S.**, Kordulakova J., Jackson M., Brosch R., Janin Y.L., Daffé M., Tillequin F., and Michel S. (2010). Synthesis, biological activity, and evaluation of the mode of action of novel antitubercular benzofurobenzopyrans substituted on A ring. *Eur. J. Med. Chem.*, 45:5833-5847. (*Impact Factor 2015: 3.902*)
19. Theodosiou T., **Vizirianakis I.S.**, Angelis L., Tsaftaris A., Darzentas N. (2011). MeSHy: mining unanticipated PubMed information using frequencies of

- occurrences and concurrences of MeSH terms. *J. Biomed. Inform.*, 44:919-926. (*Impact Factor 2015: 2.447*)
20. **Vizirianakis** I.S., Tezias S.S., Amanatiadou E.P., Tsiftoglou A.S. (2012). Possible interaction between B1 retrotransposon-containing sequences and β major globin gene transcriptional activation during MEL cell erythroid differentiation. *Cell Biol. Int.*, 36: 47-55. (*Impact Factor 2015: 1.663*)
 21. Tezias S.S., Tsiftoglou A.S., Amanatiadou E.P. **Vizirianakis** I.S. (2012). Cloning and characterization of polyA⁻ RNA transcripts encoded by activated B1-like retrotransposons in mouse erythroleukemia MEL cells exposed to methylation inhibitors. *BMB Reports*, 45:126-131. (*Impact Factor 2015: 2.782*)
 22. Chatzopoulou M., Bonovolias D.I, Nicolaou I., Demopoulos J.V, **Vizirianakis** S.I., Tsiftoglou S.A. (2012). Bis-pyrrolyl-tetrazolyl derivatives as hybrid polar compounds: a case of lipophilic functional bioisosterism with bis-acetamides. *Eur. J. Med. Chem.*, 50:75-80. (*Impact Factor 2015: 3.902*)
 23. Karagkiozaki V., Vavoulidis E., Karagiannidis P.G., Gioti M., Fatouros D.G., **Vizirianakis** I.S. and Logothetidis S. (2012). Development of a nanoporous and multilayer drug-delivery platform for medical implants. *Int. J. Nanomedicine*, 7:5327-38. (*Impact Factor 2015: 4.320*)
 24. Karavasili C., Amanatiadou E.P., Sygellou L., Giasafaki D.K., Steriotis T.A., Charalambopoulou G.C., **Vizirianakis** I.S., Fatouros D.G. (2013). Development of new drug delivery systems based on ordered mesoporous carbons: characterisation and cytocompatibility studies. *J. Mater. Chem. B*, 1:3167–3174. (*Impact Factor 2015: 4.872*)
 25. Theodoropoulos D, Rova A, Smith JR, Barbu E, Calabrese G, **Vizirianakis** IS, Tsibouklis J, Fatouros DG. (2013). Towards boron neutron capture therapy: the formulation and preliminary in vitro evaluation of liposomal vehicles for the therapeutic delivery of the dequalinium salt of bis-nido-carborane. *Bioorg. Med. Chem. Lett.*, 23:6161-6166. (*Impact Factor 2015: 2.486*)
 26. Spanakis M, **Vizirianakis** IS, Batzias G, Niopas I. (2013). Pharmacokinetic interaction between losartan and *Rhodiola rosea* in rabbits. *Pharmacology*, 91:112-116. (*Impact Factor 2015: 1.533*)
 27. Spanakis M., Bouropoulos N., Sygellou L., Ewart S., Moschovi A.M., Siokou A., Niopas I., Kachrimanis K., Nikolakis V., Cox P.A., **Vizirianakis** I.S. and Fatouros D.G. (2014). *Nanomedicine: NBM*, 10:197-205. (*Impact Factor 2015: 5.671*)
 28. Kyrodinou M, Andreadis D, Drougou A, Amanatiadou EP, Angelis L, Barbatis C, Epivatianos A, **Vizirianakis** IS. (2014). Desmoglein-3/ γ -catenin and E-cadherin/ β -catenin differential expression in oral leukoplakia and squamous cell carcinoma. *Clin. Oral Investig.*, 18:199-210. (*Impact Factor 2015: 2.207*)
 29. Fatouros DG, Lamprou DA, Urquhart AJ, Yannopoulos SN, **Vizirianakis** IS, Zhang S, Koutsopoulos S. Lipid-like self-assembling peptide nanovesicles for drug delivery. *ACS Appl. Mater. Interfaces* 2014 Jun 11;6(11):8184-9. doi: 10.1021/am501673x. Epub 2014 May 21. (*Impact Factor 2015: 7.145*)
 30. Mehta P., Arshad M.S., Justo L., Walsh S., O’Sullivan C.K., Moghimi S.M., Wilson C., **Vizirianakis** I.S., Avgoustakis K., Fatouros D.G. and Ahmad Z. (2015). New platforms for multi-functional ocular lenses: Engineering double

- sided functionalised nano coatings. *J. Drug Targeting*, 13:1-6. (*Impact Factor 2015: 2.821*)
31. **Vizirianakis IS**, Papachristou ET, Andreadis P, Zopounidou E, Matragkou CN, and Tsiftoglou AS. (2015). Genetic manipulation of RPS5 gene expression modulates the initiation of commitment of MEL cells to erythroid maturation: Implications in understanding ribosomopathies. *Int. J. Oncol.*, 47: 303-314. (*Impact Factor 2015: 3.018*)
 32. Karavasili C, Spanakis M, Papagiannopoulou D, **Vizirianakis IS**, Fatouros DG, and Koutsopoulos S. (2015). Bioactive self-assembling lipid-like peptide as permeation enhancers for oral drug delivery. *J. Pharm. Sci.*, 104(7):2304-2311. doi: 10.1002/jps.24484. (*Impact Factor 2015: 2.59*)
 33. Filippousi M, Siafaka PI, Amanatiadou EP, Nanaki SG, Neratzaki M, Bikiaris DN, **Vizirianakis IS**, Van Tendeloo G. (2015). Modified chitosan coated mesoporous strontium hydroxyapatite nanorods as drug carriers. *J. Mat. Chem. B*, 3: 5991-6000. doi:10.1039/c5tb00827a. (*Impact Factor 2015: 4.872*)
 34. Amanatiadou EP, Papadopoulos GL, Strouboulis, J, and **Vizirianakis IS**. (2015). Evidence for transcriptional regulation of ribosomal protein genes by GATA1 and PU.1 in erythroid cells: implications for ribosomopathies. *PLoS ONE*, 10(10): e0140077. DOI: 10.1371/journal.pone.0140077. (*Impact Factor 2015: 3.234*)
 35. Karavasili C, Bouropoulos N, Sygellou L, Amanatiadou EP, **Vizirianakis IS**, Fatouros DG. (2016). PLGA/DPPC/trimethylchitosan spray-dried microparticles for the nasal delivery of ropinirole hydrochloride: *In vitro*, *ex vivo* and cytocompatibility assessment. *Mater. Sci. Eng. C*, 59: 1053–1062. doi.org/10.1016/j.msec.2015.11.028. (*Impact Factor 2015: 3.420*)
 36. Grigoriadis NG, Grigoriadis IG, Markoula S, Paschopoulos M, Zikopoulos K, Apostolakopoulos PG, **Vizirianakis IS**, Georgiou I. (2016). Pharmacological preconditioning for short-term *ex vivo* expansion of human umbilical cord blood hematopoietic stem cells by filgrastim. *Am. J. Stem Cells*, 5(1): 29-38.
 37. Papanikolaou N, Pavlopoulos GA, Theodosiou T, **Vizirianakis IS**, and Iliopoulos I. (2016). DrugQuest - A text mining workflow for drug association discovery. *BMC Bioinformatics*, 17(Suppl 5):182. DOI: 10.1186/s12859-016-1041-6. (*Impact Factor 2015: 2.435*)
 38. Tseligka ED, Rova A, Amanatiadou EP, Calabrese G, Tsibouklis J, Fatouros DG, **Vizirianakis IS**. (2016). Pharmacological development of target-specific delocalized lipophilic cation-functionalized carboranes for cancer therapy. *Pharm Res.*, 33: 1945-1958. (*Impact Factor 2015: 3.260*)
 39. Makris G, Tseligka ED., Pirmettis I, Papadopoulos MS., **Vizirianakis IS.**, Papagiannopoulou D. (2016). Development and pharmacological evaluation of new bone-targeted ^{99m}Tc radiolabeled bisphosphonates. *Mol. Pharmaceut.*, 13: 2301-2317. (*Impact Factor 2015: 4.342*)
 40. Filippousi M, Turner S, Leus K, Siafaka PI, Tseligka E, Nanaki SG, Van Der Voort P, **Vizirianakis IS**, Bikiaris DN, Van Tendeloo G. (2016). Zr-based nano metal organic frameworks coated with modified poly(ϵ -caprolactone) as drug carriers. *Int. J. Pharmaceut.*, 509: 208-218. (*Impact Factor 2015: 3.994*)

41. Eleftheriadis GK, Filippousi M, Tsachouridou V, Darda M-A, Sygellou L, Kontopoulou I, Bouropoulos N, Steriotis T, Charalambopoulou G, **Vizirianakis IS**, Van Tendeloo G, Fatouros DG. (2016). Evaluation of mesoporous carbon aerogels as carriers of the non-steroidal anti-inflammatory drug ibuprofen. *Int. J. Pharmaceut.*, 515: 262-270. (*Impact Factor 2015: 3.994*)

A2. Review articles and Commentaries in peer-review journals

1. **Vizirianakis**, I.S. (2002). Pharmaceutical education in the wake of genomic technologies in drug development and personalized medicine. *Eur. J. Pharm. Sci.*, 15: 243-250. (*Impact Factor 2015: 3.773*)
2. Tsiftoglou A.S., Pappas I.S. and **Vizirianakis** I.S. (2003). The developmental program of murine erythroleukemia cells. *Oncol. Res.*, 13: 339-346. (*Impact Factor 2015: 3.957*)
3. Tsiftoglou A.S., Pappas I.S. and **Vizirianakis** I.S. (2003). Mechanisms involved in the induced differentiation of leukemia cells. *Pharmacol. Ther.*, 100: 257-290. (*Impact Factor 2015: 11.00*)
4. **Vizirianakis** I.S. (2003). New trends in modern pharmacology: From new innovative therapeutics and sophisticated drug delivery systems to pharmacogenomics and personalized medicine. (Free access at URL: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=7720007).
5. **Vizirianakis** I.S. (2004). (**Invited**). Challenges in current drug delivery from the potential application of pharmacogenomics and personalized medicine in clinical practice. *Curr. Drug Deliv.*, 1: 73-80. (*Impact Factor 2015: 1.446*)
6. **Vizirianakis**, I.S. (2005). Improving pharmacotherapy outcomes by pharmacogenomics: from expectation to reality? *Pharmacogenomics*, 6: 701-711. (*Impact Factor 2015: 2.710*)
7. **Vizirianakis**, I.S. (2007). Clinical translation of genotyping and haplotyping data: Implementation of in vivo pharmacology experience leading drug prescription to pharmacotyping. *Clin. Pharmacokinet.* 46: 807-824. (*Impact Factor 2015: 4.829*)
8. Tsiftoglou AS, **Vizirianakis** IS, Strouboulis J. (2009). Erythropoiesis: model systems, molecular regulators, and developmental programs. *IUBMB Life*, 61: 800-830. (*Impact Factor 2015: 2.653*)
9. Magklara E., **Vizirianakis** I.S. and Macheras P. (2009). Pharmacogenetics in Individualized drug therapy for brain cancer patients. *Pharmakeftiki* (Greek Journal) 22: 117-123.
10. **Vizirianakis** I.S., Chatzopoulou M., Bonovolias I.D., Nicolaou I., Demopoulos V.J., and Tsiftoglou A.S. (2010). (**Invited**). Toward the development of innovative bi-functional agents to induce differentiation and promote apoptosis in leukemia: Clinical candidates and perspectives. *J. Med. Chem.*, 53: 6779-6810. DOI: 10.1021/jm100189a. (*Impact Factor 2015: 5.589*)
11. **Vizirianakis** I.S. (2011). (**Invited**). Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug delivery outcomes. *Nanomedicine: NBM* 7(1):11-7. DOI:10.1016/j.nano.2010.11.002. (*Impact Factor 2015: 5.671*)

12. **Vizirianakis** I.S. and Fatouros D.G. (2012). **(Invited)**. Personalized Nanomedicine: Paving the Way to the Practical Clinical Utility of Genomics and Nanotechnology Advancements. *Adv. Drug Deliv. Rev.*, 64:1359-1362. *(Impact Factor 2015: 15.606)*
13. **Vizirianakis** IS. (2014). **(Invited)**. Harnessing pharmacological knowledge for personalized medicine and pharmacotyping: Challenges and lessons learned. *World J. Pharmacol.*, 3(4): 110-119.
14. **Vizirianakis IS**, Mystridis GA, Avgoustakis K, Fatouros DG, and Spanakis M. Enabling personalized cancer medicine decisions: The challenging pharmacological approach of PBPK models for nanomedicine and pharmacogenomics. *Oncol. Rep.*, 35:1891-1904. DOI: 10.3892/or.2016.4575. *(Impact Factor 2015: 2.486)*
15. Calabrese G, Daou A, Rova A, Tseligka E, **Vizirianakis IS**. Fatouros DG, Tsibouklis J. (2017). **(Invited)**. Boron containing delocalised lipophilic cations for the selective targeting of cancer cells. *Med. Chem. Commun.*, 8: 67–72. *(Impact Factor 2015: 2.319)*

A3. Book Chapters in International Editions

1. **Vizirianakis** I.S., Tsiftoglou A.S. and Sklaviadis T., (1994). Developments in slow virus research: Implication of PrP protein involvement in cell growth and differentiation. In: *“Transmissible Spongiform Encephalopathies”* (Eds. R. Bradley, and B. Marchant), pp. 421-429, Commission of the European Communities, Brussels.
2. **Vizirianakis** I.S. and Tsiftoglou A.S., (1995). Hypermethylation of RNA as part of the differentiation program of murine erythroleukemia (MEL) cells. In: *“Challenges of Modern Medicine: Differentiation Therapy”* (Ed. S. Waxman), vol. 10, pp. 263-268, Ares-Serono Symposia Publications, Rome.
3. Tsiftoglou A.S., **Vizirianakis** I.S. and Pappas I.S., (1996). Regulation of murine erythroleukemia cell differentiation. In: *“Regulation of Cell Growth, Differentiation and Genetics in Cancer”* (Eds. A.S. Tsiftoglou, A.C. Sartorelli, D.E. Housman and T.M. Dexter), vol. H 99 pp. 295- 307, Springer-Verlag Berlin Heidelberg.
4. Kramer R.H., Kantak S.S., **Vizirianakis** I.S. and Ziober B.L. (1999). Adhesion molecules in oral cancer progression. In: *“Oral Oncology”* (Ed. A.K. Varma), vol. VI, pp. 513-518, MacMillan, New York.
5. Tsiftoglou A.S., Pappas, I.S. and **Vizirianakis**, I.S. (2001). Pyridine and purine analogues as modulators of murine erythroleukemia (MEL) cell differentiation. In: *“Advanced Course on “New Fluoropyrimidines in cancer chemotherapy”*, European School of Oncology (ESO), pp. 35-39, Thessaloniki; Greece.
6. Leontiadou F., Matragou Ch., Kottakis Ph, Kalpaxis D., **Vizirianakis** I.S., Kouidou S., Tsiftoglou A.S. and Choli-Papadopoulou T. (2004). Genetic engineering of bacterial and eukaryotic ribosomal proteins for investigation on elongation arrest of nascent polypeptides and cell differentiation. In: *“Proteome and Protein Analysis”* (Eds. R.M. Kamp, J.J. Calvete and Choli-Papadopoulou T.), pp. 251-259, Springer-Verlag, Berlin, Heidelberg.

7. **Vizirianakis, I.S.** (2007). The transformation of pharmacogenetics into pharmacogenomics reinforces personalized medicine towards pharmacotyping for improved patient care. *In: "New Research on Pharmacogenetics"*, Barnes L.P. (Ed.), Nova Science Publishers, Inc.; New York. 1-38.
8. **Vizirianakis, I.S.** (2007). From defining bioinformatics and pharmacogenomics to developing information based medicine and pharmacotyping in healthcare. *In: "Pharmaceutical Biotechnology Handbook"*, Gad S.C (Ed.), John Wiley & Sons, Inc., New York, pp 201-228.
9. **Vizirianakis, I.S., Spanakis M., Termentzi A., Niopas I. and Kokkalou, E.** (2010). Clinical and pharmacogenomic assessment of herb-drug interactions to improve drug delivery and pharmacovigilance. *In: "Plants in Traditional and Modern Medicine: Chemistry and Activity"*, Kokkalou, E. (Ed.), Transworld Research Network; Kerala, India, pp. 199-234.
10. **Vizirianakis, I.S., Tezias S.S. and Tsiftoglou, A.S.** (2010). The potential role of active methylation cycle into leukemic cell differentiation. *In: "Horizons in DNA Research", Vol. 1*, Chesterton J R.. (Ed.), Nova Science Publishers, Inc.; New York, pp. 81-103.
11. **Vizirianakis I.S. and Amanatiadou E.P.** (2012). Pharmacogenomics and Nanotechnology Toward Advancing Personalized Medicine. *In: "Nanomedicine and Nanobiotechnology"*, Logothetidis S. (Ed.), NanoScience and Technology, DOI 10.1007/978-3-642-24181-9 7, Springer-Verlag; Berlin Heidelberg, pp. 115-134.
12. **Vizirianakis I.S.** (2014). Advancement of pharmacogenomics toward pharmacotyping in drug prescription: Concepts, challenges, and perspectives for personalized medicine. *In: "Handbook of Personalized Medicine: Advances in Nanotechnology, Drug Delivery and Therapy"*, Vizirianakis I.S. (Ed), pp. 893-852. Pan Stanford Publishing; Singapore.
13. **Vizirianakis I.S. Amanatiadou E.P. and Tezias S.S.** (2015). Unveiling transposable elements function to enrich knowledge for human physiology and disease pathogenesis. *In: "Genomic Elements in Health, Disease and Evolution: Junk DNA"*, Felekkis K. and Voskarides K. (Eds), pp. 109-127. Springer-Verlag; Berlin Heidelberg.
14. **Vizirianakis IS, Karavasili C., Amanatiadou EP, Fatouros DG.** (2016). Advancing the practical clinical utility in personalized medicine: Capabilities and lessons learned for pharmacology and pharmaceuticals. *In: Nanotheranostics for personalized medicine.* Couvreur P. and Mura S. (Eds), pp. 297-323. World Scientific Publishing and Imperial College Press: Singapore & London.

A.4. Publications in Greek

More than **40** research/review publications in Greek journals, National conferences and specific Greek book editions.

(A detailed list exists in my CV in Greek)

B.1. Invited speaker and presentations in scientific meetings (Selected)

1. Tsiftoglou A.S., **Vizirianakis I.S.** and Wong W., (1987). Analysis of the mechanism(s) of N⁶-methyladenosine-induced inhibition of commitment of murine erythroleukemia (MEL) cells to terminal maturation. 18th FEBS meeting, Ljubljana, Yugoslavia, Abstracts p. 274.
2. **Vizirianakis I.S.** and Tsiftoglou A.S. (1987). Implications of N⁶-methyladenosine blockade of commitment in the molecular analysis of chemically-induced differentiation of murine erythroleukemia (MEL) cells. Proc. Hellenic Biochem. Biophys. Soc., (Newsletter), 26: 34-36.
3. **Vizirianakis I.S.**, Marcopoulou C., Kountourellis J.E., Papadopoulou L.C. and Tsiftoglou A.S., (1990). RNA methylation as a key-regulatory process in growth and differentiation of murine erythroleukemia (MEL) cells: inhibition by N⁶-methyladenosine (N⁶meAdo). Proc. Amer. Assoc. Cancer Res., 31: 35.
4. **Vizirianakis I.S.**, Niopas I. and Tsiftoglou A.S. (1991). Alterations in methylation of ribosomal RNAs during differentiation of murine erythroleukemia (MEL) cells. Proc. Hellenic Biochem. Biophys. Soc., (Newsletter), 33: 21-23.
5. **Vizirianakis I.S.**, Niopas I., Marquez V.E. and Tsiftoglou A.S. (1992). Several inhibitors of DMSO-induced differentiation suppress methylation of RNA in murine erythroleukemia cells. Ann. Oncol., 3 (Suppl 1): 182.
6. Tsiftoglou A.S., Christou I.E. and **Vizirianakis I.S.**, (1992). Developmental changes in methylation of polyA⁺ RNA may regulate its stability posttranscriptionally in murine erythroleukemia (MEL) cells. Proc. Amer. Assoc. Cancer Res., 33: 48.
7. **Vizirianakis I.S.** and Tsiftoglou A.S., (1993). Induction of specific events of murine erythroleukemia cell differentiation depends on RNA methylation. Mol. Cell. Dif., 1(4): 385.
8. **Vizirianakis I.S.**, Pappas I.S. and Tsiftoglou A.S., (1995). Isolation and sequencing of a cDNA of a developmentally regulated gene encoding a S5-like rat ribosomal protein from murine erythroleukemia (MEL) cells. Proc. Hellenic Biochem. Biophys. Soc., (Newsletter), 38: 56-57.
9. **Vizirianakis I.S.**, Pappas I.S. and Tsiftoglou A.S., (1995). Isolation and characterization of cDNAs of developmentally regulated genes from murine erythroleukemia (MEL) cells. "NATO Advanced Study Institute: Regulation of cell growth, differentiation and genetics in cancer", September 1-12, Halkidiki, Greece.
10. **Vizirianakis I.S.**, Christou E-I. and Tsiftoglou A.S. (1996). Inhibition of RNA methylation leads to selective degradation of β^{major} globin mRNA in MEL cells. 24th FEBS meeting, July 7-12, Barcelona Spain.
11. **Vizirianakis I.S.** and Tsiftoglou A.S. (1997). Detection of RNA transcripts hybridized to the flanking sequences of β^{major} globin gene in murine erythroleukemia cells exposed to hypomethylating agents. Anticancer Res., 17(5C): 3965.
12. **Vizirianakis I.S.**, Chen Y-Q. and Kramer R.H. (1998). Transfection of epithelial cells with E-cadherin dominant-negative construct disrupts cell-cell adhesion. Mol. Biol. Cell, 9(supl.): 49a.

13. Gougoumas D., **Vizirianakis I.S.**, Sklaviadis T. and Tsiftoglou A.S. (1999). Transcriptional activation of prion protein (PrP) gene in growth arrested and terminally differentiated cells by chemical inducers. In the meeting "Drug Discovery '99", 22-24 September, Sandwich, Kent, U.K.
14. **Vizirianakis I.S.**, Tsiftoglou A.S. and Kramer R.H. (1999). Isolation and characterization of full-length human integrin alpha-7 cDNA. Proc. Hellenic Soc. Biochem. Mol. Biol. (Newsletter), 46: 185-189.
15. **Vizirianakis I.S.**, Tsiftoglou A.S. and Kramer R.H. (1999). The cell adhesion molecules integrins and cadherins as molecular targets for anticancer therapeutics development. Proceedings of the 1st Panhellenic Conference in Pharmacology, Published in Rev. Clin. Pharmacol. Pharmacokin. (Greek Journal-International Edition), 13: 92-93.
16. **Vizirianakis I.S.**, Chen Y-Q., Kantak S., Tsiftoglou A.S. and Kramer R.H. (2000). Alterations in adhesion, morphology, and growth of MCF-7 breast carcinoma cells transfected with a dominant-negative E-cadherin mutant. Proc. Amer. Assoc. Cancer Res., 41: 472.
17. **Vizirianakis, I.S.**, Pappas, I.S. and Tsiftoglou A.S. (2000). Cloning and expression of two cDNAs encoding the S5 and L35a ribosomal proteins in differentiating and apoptotic murine erythroleukemia (MEL) cells. Proc. Eur. Assoc. Cancer Res. 16th meeting, 30 May-3 June 2000, Halkidiki, Hellas, p. 63.
18. **Vizirianakis, I.S.** and Tsiftoglou, A.S. (2000). Detection of unique structural elements within the 3'-flanking sequences of mouse β^{major} globin gene: implications in differentiation of mouse erythroleukemia (MEL) cells. Proc. Hellenic Soc. Biochem. Mol. Biol. (Newsletter), 47: 52-55.
19. Tsiftoglou A.S., Pappas, I.S., **Vizirianakis, I.S.**, Sidiropoulou A. and Papadopoulou L.C. (2001). Mechanisms of differentiation and differentiation dependent-apoptosis (DDA) in leukemic cells. Oncol. Res., 12: 273.
20. **Vizirianakis, I.S.** and Tsiftoglou, A.S. (2002). Impact of Pharmacogenomics and other drug development technologies on modern Pharmacology and Therapeutics. Proceedings of the 2st Panhellenic Conference in Pharmacology, Published in Rev. Clin. Pharmacol. Pharmacokin. (Greek Journal-International Edition), 16: 36-37.
21. Matragou, C., **Vizirianakis, I.S.**, Tsiftoglou, A.S., Andreou-Kouidou, S. and Choli-Papadopoulou, T. (2002). Expression and structural analysis of S5 mouse ribosomal protein. "14th Meeting Methods of Protein Structure Analysis", The biennial meeting of the International Association for Protein Structure Analysis and Proteomics, Valencia, Spain, September 8th- 12th, 2002.
22. Matragou, C., Choli-Papadopoulou, T., and **Vizirianakis, I.S.** (2003). Transfection of murine erythroleukemia cells with full length ribosomal protein S5 cDNA altered the onset of erythroid differentiation. Proc. Hellenic Soc. Biochem. Mol. Biol. (Newsletter), 50: 406-410.
23. **Vizirianakis I.S.**, Tezias S.S. and Tsiftoglou A.S. (2004). DNA/RNA methylation inhibitors block murine erythroleukemia cell differentiation and promote accumulation of discrete small RNA species: Implications in activation of silent DNA sequences by pharmacological agents. Proceedings of the 3st Panhellenic Conference in Pharmacology. Rev. Clin. Pharmacol. Pharmacokin. (Greek Journal-International Edition) 18: 40-42.

24. Gougoumas D., **Vizirianakis I.S.**, Sklaviadis T. and Tsiftoglou A.S. (2004). Production of prion protein (PrP^C) in transfected murine erythroleukemia (MEL) and neuronal N2a cells overexpressing PrP RNA transcripts. Proceedings of the 3rd Panhellenic Conference in Pharmacology. Rev. Clin. Pharmacol. Pharmacokin. (Greek Journal-International Edition), 18: 43-44.
25. Tsiftoglou A.S., Gougoumas D., Masiou S. and **Vizirianakis I.S.** (2004). Exploring the role of apoptosis in erythroid cell differentiation with the use of murine erythroleukemia (MEL) cell system. Keystone Symposia: "HEMATOPOIESIS", Tahoe City, California, March 12-17, 2004; Abstract Book p. 68.
26. **Vizirianakis I.S.** (2004). (**Invited**). *Pharmacoeconomics and Rational Drug Prescription: The Example of Alzheimer's Disease*. Invited contribution to the meeting "Neuroscience Forum", July 10-11, Paphos, Cyprus.
27. Matragkou, C., **Vizirianakis, I.S.**, Papamarcaki, T., Karetsoy, Z., Tsiftoglou, A. S. and Choli-Papadopoulou, T. (2004). On the possible involvement of mouse rpS5 phosphorylation in ribosomal biogenesis and cellular differentiation. 15th Meeting "Methods in Protein Structure Analysis" August 29 to September 2, 2004, Seattle, Washington, U.S.A.
28. Pappas I.S., Lambris J., **Vizirianakis, I.S.**, Winter M.S. and Tsiftoglou A.S. (2004). Detection of inducer-binding protein(s) in murine erythroleukemia and neuroectodermal cells. Presentation at the 56th meeting of the HSBMB, November 25-27, Larissa, Greece. Proc. Hellenic Soc. Biochem. Mol. Biol. (Newsletter), vol. 51, Larissa 2004.
29. Triviai, I.N., Masiou, S.D., Markala, D.G., Pappas, I.S., **Vizirianakis, I.S.** and Tsiftoglou A.S. (2005). Evidence for induction of apoptosis in differentiating murine erythroleukemia (MEL) cells: Implications in leukemia therapy. European Cell Death Organization Meeting, October 1-4, 2005, Budapest.
30. Tezias S.S., Tsiftoglou A.S. and **Vizirianakis I.S.** (2006). The potential role of β^{major} globin gene 3'-flanking sequences in inhibition of MEL erythroid differentiation by hypomethylating agents. Proceedings of the 4th Panhellenic Congress of Pharmacology, May 19-20, 2006, Patras. Rev. Clin. Pharmacol. Pharmacokin. (Greek Journal-International Edition), 20: 114-116.
31. Papachristou E.T., Matragkou C., Triviai I.N., Tezias S.S., Tsiftoglou A.S., Choli-Papadopoulou T. and **Vizirianakis I.S.** (2006). The potential involvement of ribosomal protein S5 in the initiation of MEL erythroid cell differentiation and apoptosis. Proceedings of the 4th Panhellenic Congress of Pharmacology, May 19-20, 2006, Patras. Rev. Clin. Pharmacol. Pharmacokin. (Greek Journal-International Edition), 20: 276-278.
32. Matragkou C., Papachristou E.T., Karetsoy Z., Papamarcaki T., Tsiftoglou A.S., **Vizirianakis I.S.** and Choli-Papadopoulou T. (2006). The NH2-terminal 1-37 region of ribosomal protein S5 from mouse regulates its intracellular trafficking. 58th Panhellenic Congress of Hellenic Society of Biochemistry and Molecular Biology. November 9-11, 2006, Patras.
33. Vizirianakis, I.S. (2007). (**Invited**). The potential role of ribosomal protein S5 in MEL cell differentiation: A transfection/RNAi approach. Invited contribution to the workshop "Cancer research: Molecular, cellular & therapeutic aspects of cancer". June 1, 2007, Thessaloniki, Greece.

34. Matragkou C., **Vizirianakis I.S.**, Papamarcaki T., Karetsou Z., Tsiftoglou, A.S., and Choli-Papadopoulou, T. (2007). On the possible involvement of mouse rpS5 phosphorylation in ribosomal biogenesis and cellular differentiation *Amino Acids* 33(3), pp. XLIX-L.
35. **Vizirianakis I.S.** (2007). (**Invited**). The advent of pharmacogenomics and the new era in drug delivery and pharmacovigilance. *13th Panhellenic Pharmaceutical Congress*. May 12-14, 2007, Athens. *Eur. J. Drug Metab. Pharmacokinet.* 32:77.
36. Papachristou E.T. and **Vizirianakis I.S.** (2008). RNAi-mediated silencing of ribosomal protein S5 gene expression blocks the initiation of MEL cell erythroid differentiation in vitro. *33rd FEBS Congress*, June 28-July 3, 2008, Athens; *FEBS J.* 275(S1): 227.
37. Tezias S.S., Tsiftoglou A.S. and **Vizirianakis I.S.** (2008). Cloning and characterization of discrete non-poly(A) RNA transcripts derived from silent 3'-end flanking β^{major} globin gene DNA sequences induced upon blockade of MEL cell differentiation by DNA/RNA methylation inhibitors. *33rd FEBS Congress*, June 28-July 3, 2008, Athens; *FEBS J.* 275(S1): 132.
38. Chatzopoulou M., Bonovolias I., Polyxeni A., Nicolaou I., **Vizirianakis I.S.**, Demopoulos V. and Tsiftoglou A.S. (2009). In search of new potent inducers of cell differentiation for leukemia therapy. *Joint Meeting on Medicinal Chemistry*, June 24-27, Budapest, Hungary. *Book of Abstracts* p. 92.
39. **Vizirianakis, I.S.** (2009). (**Invited**). Epigenetic regulation of erythropoiesis and methylation inhibitors. Invited contribution to the Mini Symposium "Erythropoiesis and Related Hematological Disorders". June 26, 2009, Thessaloniki.
40. Matragkou C, Papachristou H, Karetsou Z, Papadopoulos G, Papamarcaki T, **Vizirianakis IS**, Tsiftoglou AS, Choli-Papadopoulou T. (2009). On the Intracellular Trafficking of Mouse S5 Ribosomal Protein from Cytoplasm to Nucleoli. *60th Meeting of Hellenic Society of Biochemistry and Molecular Biology*, November 20-22, 2009, Athens. *Books of Abstracts* vol. 55, p. 40.
41. Andreadis D., Kyrodinou M., Barbatis C., Amanatiadou E., Drougou A., Pouloupoulos A., Tsopanomichalou M., Kalekou-Greca H., Epivatianos A. and **Vizirianakis I.S.** (2010). Differential desmogleins-2/3 and gamma-catenin expression in oral leukoplakia/squamous-cell carcinoma. *International Association for Dental Research (IADR) meeting*, July 14-17, 2009, Barcelona, Spain.
42. Spanakis M., **Vizirianakis I.S.** and Niopas I. (2010). Modulation of P-glycoprotein mediated drug transport in Caco-2 cells by *Aloe Vera* phytotherapeutic products: A methodology to evaluate drug-herb interactions in clinical practice. *6th Panhellenic Congress of Pharmacology*, June 4-6, 2010, Heraklion; *Rev. Clin. Pharmacol. Pharmacokin.* (Greek Journal-International Edition), 24: 211-213.
43. **Vizirianakis, I.S.** (2010). (**Invited**). Nanomedicine & Personalized Medicine: The improvement of drug delivery outcomes by pharmacogenomics leading to pharmacotyping in clinical practice. Invited contribution to the meeting "7th International Conference on Nanosciences and Nanotechnologies", July 11-14, 2010, Ouranoupolis, Halkidiki Greece.

44. **Vizirianakis, I.S.** (2011). **(Invited)**. Toward Advancing the Development of Innovative Molecularly-Targeted Antileukemia Therapeutics: Challenges for Molecular Pharmacology and Nanomedicine. Invited contribution to the meeting “8th International Conference on Nanosciences and Nanotechnologies”, July 12-15, 2011, Thessaloniki, Greece.
45. **Vizirianakis, I.S.** (2012). **(Invited)**. Uncovering Crucial Molecular Mechanisms of Erythropoiesis to Enable Innovative Therapeutic Approaches for Erythroid Disorders. Invited contribution to the meeting “9th International Conference on Nanosciences and Nanotechnologies”, July 3-7, 2012, Thessaloniki, Greece.
46. **Vizirianakis, I.S.** (2012). Blockade of Murine Erythroleukemia (MEL) Cell Maturation by Methylation Inhibitors: Lessons Learnt and Challenges for Molecular Pharmacology. Contribution to the 1st Workshop of the COST Action CM1106, July 3-5, 2012, Milano, Italy.
47. **Vizirianakis, I.S.** (2013). **(Invited)**. Personalized nanomedicine crossing the borderlines between pharmacogenomics and nanotechnology to advance cancer therapeutics decisions. Invited contribution to the 5th BBBB International Meeting, September 26-28, 2013, Athens, Greece.
48. Spanakis M., **Vizirianakis I.S.**, Niopas I. Application of the Simcyp[®] simulation in the pharmacokinetic drug-herb interaction study of losartan with *Rhodiola rosea*. Presentation in the 5th BBBB International Meeting, September 26-28, 2013, Athens, Greece.
49. Cox P.A., Nikolakis V., **Vizirianakis I.S.**, Dodd J.L., Slingo J. and Fatouros D.G. (2013). Molecular Dynamics Studies of Drug Delivery via Zeolites. Poster presentation in the 17th International Zeolite Conference (17th IZC), July 7–12, 2013, Moscow, Russia.
50. **Vizirianakis, I.S.** (2013). **(Invited)**. Personalized nanomedicine: Toward advancing the practical clinical utility of translational medicine decisions. Invited contribution to the 10th International Conference on Nanosciences and Nanotechnologies, July 9-12, 2013, Thessaloniki, Greece.
51. **Vizirianakis, I.S.** (2014). **(Invited)**. Advancing the practical clinical utility in personalized medicine: Capabilities and lessons learned. Invited contribution to the 11th International Conference on Nanosciences and Nanotechnologies, July 8-11, 2014, Thessaloniki, Greece.
52. Amanatiadou E.P., Karavasili C., **Vizirianakis I.S.**, Fatouros D.G. (2014). Development of spray-dried microparticles containing ropinirole hydrochloride: Physicochemical characterization and cytocompatibility assessment. 65th Congress of the Hellenic Society of Biochemistry and Molecular Biology. November 28-30 2014, Thessaloniki, Greece.
53. Amanatiadou E.P., **Vizirianakis I.S.** (2014). In vitro binding of transcription factors GATA-1 and PU1 to the mouse RPS5 proximal promoter region. 65th Congress of the Hellenic Society of Biochemistry and Molecular Biology. November 28-30 2014, Thessaloniki, Greece.
54. Gkotinakou I.M., Befani C., **Vizirianakis I.S.**, Tsiftoglou A.S., Simos G., Liakos P. Effect of hypoxia and HIFs on K562 human erythroleukemia cell differentiation. *65th Congress of the Hellenic Society of Biochemistry and Molecular Biology*. November 28-30 2014, Thessaloniki, Greece.

55. Filippousi M, Turner S, Leus K, Siafaka PI, Tseligka E, Nanaki SG, Van Der Voort P, **Vizirianakis IS**, Bikiaris DN, Van Tendeloo G. (2015). Zr-based nano metal organic frameworks coated with modified poly(ϵ -caprolactone) as drug carriers. NANOBIOAPP2015: Latest Advances on Carbon Nanomaterials for Biomedical Applications, 21-23 September 2015, Barcelona, Spain.
56. **Vizirianakis IS** (2015). (**Invited**). Toward Personalized Cancer Therapy: Challenges and Lessons Learned for Medicine and Pharmacy. Webinar School of Pharmacy, University of Qatar, March 30, 2015.
57. **Vizirianakis IS** (2015). (**Invited**). Toward balancing cellular toxicity and selectivity upon developing innovative bifunctional anticancer therapeutics. 12th International Conference on Nanosciences & Nanotechnologies (NN15), 7-10 July 2015, Thessaloniki, Greece.
58. **Vizirianakis IS**. (2016). (**Invited**). Genomic Elements in Health, Disease and Evolution–Junk DNA. Book presentation. (Felekkis K., Voskarides K., Eds; Springer-Verlag: Berlin). March 17, 2016, Nicosia, Cyprus.
59. **Vizirianakis IS**. (2016). (**Invited**). Personalized Medicine and Pharmacogenomics: Challenges and Perspectives. *Exploring Novel Medical Frontiers 2016 (ENMF 2016)*. April 9-10, 2016, Thessaloniki, Greece.
60. **Vizirianakis IS**. (2016). (**Invited**). Contemporary pharmaceutical and medical practice: Scientific perspectives and professional challenges. *1st Pharmaceutical Conference of Eastern Macedonia and Thrace “Opening the horizons for the Greek community pharmacy”*. May 28-29, 2016, Komotini, Greece.
61. **Vizirianakis IS** (2016). (**Invited**). Pharmacological development of target-specific delocalized lipophilic cation-functionalized carboranes for cancer therapy. *13th International Conference on Nanosciences & Nanotechnologies (NN16)*. 5-18 July 2016, Thessaloniki, Greece.
62. **Vizirianakis IS**. (2016). (**Invited**). Harnessing pharmacological knowledge for enabling drug delivery in personalized medicine. 2nd International Congress of Controlled Release Society – Greek Local Chapter. June 22-24 2016, Athens Greece.
63. Amanatiadou EP, Karavasili C, Eleftheriadis GK, Kontogiannidou E, **Vizirianakis IS**, Fatouros DG. (2016). Pharmacological assessment of hierarchical zeolites BEA, NAX-FAU and ZSM5 for oral delivery of poorly soluble drugs. *2nd International Congress of Controlled Release Society – Greek Local Chapter*. June 22-24 2016, Athens Greece.
64. Eleftheriadis GK, Akrivou M, Bouropoulos N, **Vizirianakis IS**, Fatouros DG. (2016). Dry powders of hybrid lipid-polymer microparticles for pulmonary delivery of budesonide. *2nd International Congress of Controlled Release Society – Greek Local Chapter*. June 22-24 2016, Athens Greece.
65. Eleftheriadis GK, Kontogiannidou E, Bouropoulos N, Vouvoudi E, Achilias D, Ritzoulis C, **Vizirianakis IS**, Fatouros DG. (2016). 3D Printed mucoadhesive films for buccal delivery of non-steroidal anti-inflammatory drugs. *2nd International Congress of Controlled Release Society – Greek Local Chapter*. June 22-24, 2016, Athens Greece.
66. Akrivou M, Demertzidou V, Theodoroula N, Grigoriadis N, Zografos A, **Vizirianakis IS**. (2016). Assessing the pharmacological profile of new synthetic

sesquiterpene VDS58 that activates p21 gene expression in cancer cells. *67th Hellenic Society for Biochemistry and Molecular Biology (HSBMB) Conference*. November 25-27, 2016, Ioannina, Greece.

67. Amanatiadou EP, **Vizirianakis IS**. (2016). Assessing the effects of the ectopic expression of ribosomal protein RPL35A in murine erythroleukemia cell differentiation program. *67th Hellenic Society for Biochemistry and Molecular Biology (HSBMB) Conference*. November 25-27, 2016, Ioannina, Greece.
68. **Vizirianakis IS**. (2016). Harnessing pharmacological knowledge in the era of precision cancer therapeutics. *Hellenic Bioinformatics 09 Conference*. 19-21 November, 2016, Thessaloniki, Greece.
69. Paparidis G, Shegani A, Tsachouridou V, Akrivou M, **Vizirianakis IS**, Bouzioti P, Pirmettis I, Papadopoulos M, Papagiannopoulou D. (2017). Development of a new $^{99m}\text{Tc}(\text{CO})_3^+$ Chelate of the Triphenylphosphonium Cation as a Potential Tumor Imaging Agent. *22nd International Symposium on Radiopharmaceutical Science (ISRS2017)*. May 14-17, 2017, Dresden, Germany.
70. **Vizirianakis IS**. (2017). Advances in Pharmacological Research and Personalized Medicine: Opportunities and Challenges for Therapeutics and Pharma Industry. *1st Symposium of the PharmaInformatics Unit of ATHENA' Research and Innovation Center*. February 13, 2017, Athens.
71. Paparidis G., Akrivou M., Tsachouridou V., Shegani A., **Vizirianakis IS.**, Bouzioti P., Pirmettis I., Papadopoulos MS., Papagiannopoulou D. (2017). Development of a New Technetium-99m Tricarbonyl Chelate of the Triphenylphosphonium Cation as Potential Tumor Imaging Agent. *3rd Panhellenic Congress of Pharmacy Schools*. February 18-19, 2017, Thessaloniki, Greece.
(For a more detailed list see my CV in Greek).

B.2. Invited presentations in National scientific meetings

More than **30** invited contributions into national scientific meetings.

(For a more detailed list see my CV in Greek).